Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epcoritamab + loncastuximab tesirine
- Development stage
- Unknown
- Lead developer
- Genmab
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Epcoritamab + loncastuximab tesirine is a combination therapy being investigated for the treatment of relapsed or refractory large B-cell lymphoma (LBCL). Epcoritamab is a bispecific T-cell engager (BiTE) that simultaneously binds to CD3 on T cells and CD20 on B cells, facilitating T-cell-mediated lysis of malignant B cells. Loncastuximab tesirine is a CD19-directed antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer cytotoxic alkylating agent. The combination aims to enhance anti-tumor activity by targeting multiple B-cell antigens (CD19 and CD20) and employing distinct mechanisms of action, including T-cell recruitment and direct DNA damage. This regimen is currently being evaluated in a Phase 2 clinical trial led by the University of Miami.
- Brand names
- EpkinlyZynlonta
- Other names
- Epcoritamab and Loncastuximab TesirineEpcoritamab-DuoBodyLonca
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD20 (B-lymphocyte antigen CD20)CD19 (B lymphocyte antigen CD19)DNA
Beyond the preview
Go deeper on epcoritamab + loncastuximab tesirine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epcoritamab + loncastuximab tesirine.